[account_shop_links]
South Korea: Clinical Development Country Profile
$2,960.00 – $5,920.00
Licensing Options
- SINGLE-USER LICENSE
A Single-User License allows access to an individual user.
- ENTERPRISE-WIDE LICENSE
An Enterprise-Wide License allows access to all employees and sites within an organization.
Report Overview
In this report, ISR provides insight into the clinical development environment, sponsor and service provider activities, and population “health status” for South Korea.
Why should South Korea be a part of your development plan?
- South Korea has seen rapid growth in the number of clinical trials performed from 33 in 2000 to 439 in 2010
- IMS is calling for a 6.5% CAGR in drug spending through 2015
- Recent fair trade agreements between the US and South Korea could mean more trade and better IP protection
- South Korea has one of the most advanced telecommunications infrastructures in the world with 95% of the population having internet access
What you will learn:
- How population characteristics, qualified investigators, and government policies and incentives make South Korea the 8th most active and most valuable country for clinical trial activity
- On-the-ground insights from numerous high-level R&D employees in sponsor organizations and country heads from multinational CROs
- Health statistics in Korea, including disease incidence and prevalence, use of imaging technologies, and use of medicines in major therapy areas
- Compiled lists and contact details for pharma companies, service providers, and ### principal investigators in South Korea
How you can use this report:
- Understand how sponsors and CROs view South Korea as a site for clinical trials, understand logistical details for conducting South Korean trials, and illustrate the benefits and drawbacks of conducting trials in South Korea
- View into how South Korea compares to other countries on a variety of scales so the reader can best consider the areas in which South Korea may be beneficial as a trial site for their particular company
Report Contents:
- Introduction
- Industry Interviews
- Korea Health Statistics
- Healthcare Technology and Medication Use
- Service Provider Capabilities
- Domestic Clinical Service Providers
- Domestic Non-Clinical Service Providers
- Domestic Service Provider Contact Summary
- International CRO List and Contact Details
- Domestic Pharma Company List and R&D Expenditure
- International Pharma Company List and Locations
- Clinical Investigator List and Contact Details
